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Abstract
Histopathology is the microscopic examination of processed human tissues to diag-
nose conditions like cancer, tuberculosis, anemia and myocardial infractions. The
diagnostic procedure is, however, very tedious, time-consuming and prone to misin-
terpretation. It also requires highly trained pathologists to operate, making it un-
suitable for large-scale screening in resource-constrained settings, where experts are
scarce and expensive.
In this thesis, we present a software system for automated screening, backed by deep
learning algorithms. This cost-effective, easily-scalable solution can be operated by
minimally trained health workers and would extend the reach of histopathological
analyses to settings such as rural villages, mass-screening camps and mobile health
clinics. With metastatic breast cancer as our primary case study, we describe how
the system could be used to test for the presence of a tumor, determine the precise
location of a lesion, as well as the severity stage of a patient. We examine how
the algorithms are combined into an end-to-end pipeline for utilization by hospitals,
doctors and clinicians on a Software as a Service (SaaS) model. Finally, we discuss
potential deployment strategies for the technology, as well an analysis of the market
and distribution chain in the specific case of the current Indian healthcare ecosystem.
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Chapter 1
Introduction
The field of pathology deals with providing clinical disease diagnoses to inform pa-
tient treatment and management. Accurate and reproducible pathology diagnoses are
essential for precision and targeted medicine. The primary tool used by pathologists
has been the microscope, followed by a qualitative visual analysis [1] [39]. However,
this has been limited by lack of standardized agreement between pathologists, as well
as diagnostic errors arising from the task of manually analyzing gigapixel images for
millions of cells across hundreds of slides on a daily basis [45] [49] [8], with inter-rater
agreement sometimes as low as 48%, and only 70% on average. [17].
1.1 Motivation
As a case study for a particular pathology, we consider detecting metastatic breast
cancer in digital whole slide images of lymph node biopsies. (Figure 1-1) According to
the American Joint Committee on Cancer [16], a patient with sentinel lymph nodes
diagnosed to be positive for breast cancer is assigned a more severe pathological
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stage, with more aggressive interventions (like auxiliary lymph node dissection) than
a patient with a negative result [43] [44] [3].
The manual visual analysis of sentinel lymph node slides is tedious, repetitive and
laborious, especially for negative cases or cases with only very small affected regions.
This often results in diagnostic errors and false negatives. Chemical alternatives for
analysis like immunohistochemistry are limited by increased cost, increased processing
and increased number of slides required, with little improvement in accuracy. [14].
The development of effective and cost-efficient computer-assisted image analysis sys-
tems for lymph node evaluation remains an area of active research, as a high-performing
system which could improve accuracy while reducing cognitive load would be highly
valuable. [34]
In this thesis, we present a deep learning based approach for histopathological analy-
ses, specifically identification and localization of breast cancer metastases from whole
slide images of sentinel lymph nodes. We further study how these analyses from mul-
tiple slides for a patient can be synthesized into an estimate of the clinical stage of
the patient, and how these methods can be evaluated and compared to the state-of-
the-art.
Additionally, we further present an analysis of how the algorithms can be combined
into an end-to-end system for deployment, and what those deployment opportunities
and challenges could be in the specific case of the Indian healthcare system.
1.2 Contributions
This thesis makes important contributions in showing how deep learning solutions can
be used to automate histopathological analyses at scale, lowering cost and extending
15
Figure 1-1: Lymph nodes are small glands that filter lymph, a colorless fluid con-
taining white blood cells that bathes the tissues and drains through the lymphatic
system into the bloodstream. Metastatic involvement of lymph nodes is one of the
most important prognostic factors in breast cancer. They are surgically removed
and examined microscopically, as in the whole-slide images analyzed in the following
chapters. (Illustration adapted from the National Breast Cancer Foundation [21])
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reach in resource-constrained settings. In the subsequent chapters, we describe in
detail the following -
" Algorithms for identifying and classifying whole slide images of sen-
tinel lymph nodes for metastatic breast cancer.
- A split-and-recombine strategy to train convolutional neural networks and
employ them for localized predictive inference.
- An aggregation framework for post-processing likelihood maps into whole-
slide classification results.
" Algorithms for precise automated localization of suspected tumor
sites in whole slide images.
- A two-stage deep thresholding model which uses connected components in
the likelihood maps to identify tumor locations.
- A region proposal network which learns to identify areas of potentially
high information to guide search for tumor boundaries.
" Algorithms for synthesizing evaluations of multiple slides from differ-
ent lymph nodes to characterize the clinical stage of a patient.
- A rule-based learner which incorporates guidelines followed by pathologists
to rate clinical stage.
- A joint learning model for both likelihood and stage, which is able to
encode information not captured by the guidelines.
" Analyses of deployment strategies for the software solution in India.
- A study of the key customer segments and stakeholders and promising
business models in the Indian healthcare industry.
17
- An analysis of factors required to set up a sustainable platform and a chain
for distribution.
18
Chapter 2
Background and Related Work
The conventional qualitative visual analysis for histopathological images relies on the
digital imaging technologies employed to capture the relevant tissue image, and the
expertise of the trained pathologist. The work presented in this thesis aims to present
a number of methods to augment or enhance the latter component with computer
vision and deep learning techniques. In this respect, this work draws from three
broad areas - digital pathology, traditional computer vision and recent advances in
deep learning. Following are key developments in each field which form the basis of
this work.
2.1 Digital Pathology
Tissue samples for pathological analyses are usually collected via surgery or via biopsy,
and need to be further processed in order to make glass slides which hold histological
sections of the thickness of a few micrometers. This processing includes fixation, em-
bedding, cutting and staining. During the preparation of histological slides, different
19
stains can be used for various purposes, but the hematoxylin and eosin (H&E) stain
is most widely used; it induces sharp blue/pink contrasts across various sub-cellular
structures and it is applied across many different tissue types.
Digital Imaging for pathology has gained acceptance in the last decade as the de facto
representation modality, for easy access and archiving [23]. Whole-slide scanners are
used to digitize glass slides at high resolution (up to 160nm per pixel). The availability
of whole-slide images (WSI) has sparked the interest of the medical image analysis
community, resulting in increasing numbers of publications on histopathological image
analysis.
These whole-slide images are generally stored in multi-resolution TIFF pyramid files.
Image files contain multiple down-sampled versions of the original image. Each image
in the pyramid is stored as a series of tiles, to facilitate rapid retrieval of subregions
of the image.
A typical whole-slide image is approximately 200,000 x 100,000 pixels on the highest
resolution level with 3 byte RGB pixel format. This translates into over 56 GB of
uncompressed pixel data from a single level. This has resulted in a need for clever
techniques to efficiently handle and process such amounts of data.
2.2 Classical Computer Vision
Over the past decades, there has been an increased interest in computational methods
for assistance in analysis of microscopy images in pathology. [27]
Historically, approaches to histopathological image analysis in digital pathology have
focused primarily on low-level image analysis tasks (e.g., color normalization, nu-
clear segmentation, and feature extraction), followed by construction of classification
20
models using classical machine learning methods, including: logisitic regression, sup-
port vector machines, and random forests. Typically, these algorithms take as input
relatively small sets of image features (10-100) [27] [32]. Further building on this
framework, approaches have been developed for the automated extraction of moder-
ately high dimensional sets of image features (1000s) from histopathological images
followed by the construction of relatively simple, linear classification models using
methods designed for dimensionality reduction, such as sparse regression [5].
2.3 Deep Learning
Since 2012, deep Convolution Neural Networks have significantly boosted accuracy on
a wide range of computer vision tasks, including image recognition [38] [31] [52], object
detection [25] [24] [50] and semantic segmentation [42]. They have also been employed
productively in healthcare applications, notably detection of diabetic retinopathy
from retinal fundus photographs [26], and dermatologist-level detection of melanoma
from skin photographs [20].
In the context of histopathology, there have been studies in applying the above tech-
niques to detect prostate cancer biopsies [41] and to segment epithelium, tubules, lym-
phocytes, mitosis and lymphoma [35]. It has been demonstrated that CNNs achieved
higher F1 score and balanced accuracy in detecting invasive ductal carcinoma.[13].
Mitosis detection competitions at ICPR 2012 [10] and AMIDA 2013 [61] have been
won by teams which used CNNs. Predicting prognosis in non-small cell lung cancer
using machine learning was described in [63]. In contrast to the types of machine
learning approaches historically used in digital pathology, in deep learning-based ap-
proaches there tend to be no discrete human-directed steps for object detection, object
segmentation, and feature extraction. Instead, the deep learning algorithms take as
input only the images and the image labels (e.g., 1 or 0) and learn a very high-
21
dimensional and complex set of model parameters with supervision coming only from
the image labels.
It has been hypothesized that deep learning techniques could increase the sensitivity,
speed and consistency of metastasis detection, but so far no systems have been able
to deliver on those fronts to a clinically acceptable standard. [41]
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Chapter 3
Algorithms for Lesion
Classification
Classifying whole-slide images of sentinel lymph node tissues extracted from suspected
patients into normal or tumor is an important, and often critical, prognostic step for
the pathologist. In this chapter, we describe the dataset we used to train our models
on, the evaluation metrics to judge performance, the classification pipeline, and close
with a discussion of the results.
3.1 Dataset
Whole-slide scanners (Figure 3-1) were used to collect images of sentinel lymph node
tissues after fixation, embedding, cutting and staining by hematoxylin and eosin
(H&E). These scanners can reach resolutions of upto 160 nanometer per pixel, and
output images at multiple scanning resolutions in a pyramid structure (Figure 3-
2). The data was collected by the Diagnostic Image Analysis Group (DIAG) and
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Department of Pathology of the Radboud University Medical Center (Radboudumc)
in Nijmegen, The Netherlands, and made available publicly in the Camelyon challenge
[22].
The data consists of a total of 400 whole-slide images of sentinel lymph nodes, split
into a training set of 270 slides (160 normal, 110 tumor), and a test set of 130 slides.
The ground truth data for the training slides consists of a pathologists delineation
of regions of metastatic cancer on WSIs of sentinel lymph nodes. The data was
provided in two formats: XML files containing vertices of the annotated contours of
the locations of cancer metastases and WSI binary masks indicating the location of
the cancer metastasis.
Figure 3-1: A typical whole-slide scanner system (courtesy of OptraScan [47]). These
solutions can scan over 120 slides at once, with the option of 10x, 20x or 40x mag-
nification. The output is usually in multi-resolution TIFF image pyramids and of
resolutions in the order of 200,000 x 100,000 pixels at highest magnification.
3.2 Evaluation Metrics
The whole slide classification task between metastasis and normal slides is assessed by
the means of the area under (AUC) the receiver operating characteristic (ROC) curve,
which is a graphical plot that illustrates the performance of a binary classifier system
24
Structure of a TIFF image pyramid file - the output of a whole slide
scanner. It usually is a 3 channel image over multiple optical resolutions (the highest
magnification can reach 160 nm per pixel), for easy retrieval of relevant subregions.
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Figure 3-3: Slide samples at highest magnification
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Figure 3-2:
as its discrimination threshold is varied. It is created by plotting the true positive
rate (TPR) against the false positive rate (FPR) at various threshold settings. The
true-positive rate is also known as sensitivity or recall, while the false-positive rate is
also known as the fall-out or probability of false alarm and can be calculated as (1
specificity). The ROC curve is thus the sensitivity as a function of fall-out [4]. For
each image in the test set, the algorithm ultimately provides the probability of that
image to contain metastasis.
3.3 Classification Pipeline
Because of the extremely large size of each slide and the limited number of slides, we
divide each whole-slide image into small square patches and train a deep convolutional
neural network to make patch-level predictions to discriminate tumor-patches from
normal-patches. We then aggregate the patch-level predictions to create tumor likeli-
hood heatmaps and perform post-processing over these heatmaps to make predictions
for the slide-based classification task (and later the tumor-localization task).
3.3.1 Pre-processing
The whole slide images invariably contain a lot of negative space (80%), which greatly
increases computation time (with each image being 56 GB uncompressed). To re-
duce the required compute and to focus on the regions most likely to contain cancer
metastasis, we identify the tissue the image. This is achieved by an unsupervised
thresholding process -
e The image is transformed from RGB to HSV cylindrical-coordinate color space
to reduce dependence of the procedure on lighting and contrast. The color (Hue,
Saturation channels) is separated from the lighting (Value channel). [2]
26
Figure 3-4: Example of a whole-slide image with macro-metastases. The structures
outlined in green represent the tumors in the sample (according to the pathologist-
labeled ground truth annotations). At high magnification, the differences in local
texture between the normal and metastatic regions. However, as later discussed,
these differences can often be very subtle.
J
J
27
" Optimal threshold values are computed for each channel with Otsu's algorithm
for binary segmentation [48], which minimizes intra-class variance or equiva-
lently, maximizes inter-class variance.
" A union is performed for the mask for H and S channels, and then its intersection
with the original whole-slide image is taken as the new data source.
The reduction in area to consider is shown in Figure 3-5, with the threshold boundaries
identified in green. On an average 81% of the data per whole-slide image is removed
with this process, making subsequent steps computationally tractable.
We also perform stain specific standardization of the whole-slide images, analogous
to that described in [6], to make the process invariant to most inconsistencies in the
composition of the stain and the process of applying it. In order, we
1. Transform to the Hue-Saturation-Density space
2. Extraction samples for the hematoxylin, eosin and background classes from the
WSI and derive the chromatic and density distributions of these classes.
3. Transform the 2D chromatic distribution for each dye class to match the chro-
matic distribution of the corresponding class from a template slide.
4. Transform the density distribution for each dye class to match the density dis-
tribution of the corresponding class from a template slide.
5. Weigh the contribution of stains for each pixel and obtain final chromatic and
density transformations.
6. Apply inverse HSD transform.
28
(a) (b)
Figure 3-5: Results of background removal. The green lines delineate the regions
ultimately processed by the subsequent steps. On an average, 81% of the data is
culled.
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3.3.2 Data Augmentation
In order to further make the classifier robust to variance in orientation, stain color and
other small perturbances, we augment our dataset with artificially generated samples
" We perform random translations by cropping a 224x224 subregion from the
patch.
* We perform random horizontal flips and rotations by 90 degree multiples.
" We perform random aspect ratio modifications in the range 3/4 to 4/3.
" We perform color perturbation by adding to the RGB channels multiples of their
principal components, scaled by the eigenvalues times a normal random variable
drawn from N(0, 1). i.e. to each RGB image pixel I,, = [Iv, I VG I XB]T we
add the quantity
[PI, P2,i P31 [a1I-, a2'72, a37Y31,
where p and 7y are ith eigenvector and eigenvalue of the 3 x 3 covariance matrix
of RGB pixel values, respectively, and a, is the aforementioned random variable.
This scheme approximately captures an important property of natural images,
namely, that object identity is invariant to changes in the intensity and color of
the illumination.
" We add jitter to the patch extraction process so that each patch has a small x,y
offset of up to 8 pixels.
The modifications are performed on-the-fly during training so that the transformed
images need not be stored on disk, and sequenced on the CPU while the GPU is
processing the last batch, severely reducing computational needs.
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3.3.3 Patch-based Classification
The patch-based classification stage takes as input whole slide images (of resolution
in the order of 200,000 x 100,000 pixels) and the ground truth image annotation
delineating the locations of regions of each WSI containing metastatic cancer. We
randomly extract millions of small (256 x 256 pixels) positive and negative patches
from the set of training WSIs. If the small patch is located in a tumor region, it is a
tumor / positive patch and labeled with 1, otherwise, it is a normal / negative patch
and labeled with 0. On an average, we extract, without overlap, 1000 positive and
1000 negative samples from each tumor image (and only the latter from a normal
images). This results in a total of 110,000 positive and 270,000 negative data points,
representative samples of which are illustrated in Figure 3-4.
Following selection of positive and negative training examples, we use a deep neu-
ral network to train a supervised classification model to discriminate between these
two classes of patches. Deep learning enables a hierarchy of processing layers to au-
tomatically learn representation of data with an increasing level of abstraction. It
discovers intricate structure in large data sets by using the backpropagation algo-
rithm to suggest how the computer should change its internal parameters that are
used to compute the representation in each layer from the representation in the pre-
vious layer. Deep convolutional networks have recently brought about breakthroughs
in processing images, video, speech and audio. [40]
This is in sharp contrast to conventional machine-learning techniques which require
careful engineering and considerable domain expertise to design a feature extractor
that transformed the raw data into a suitable internal representation or feature vector
from which the learning subsystem could detect patterns in the input. The key
disadvantage of the using classical linear classifiers (which compute a weighted sum
of the feature vector and compare it to a threshold) in the network is their limitation of
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only being able to carve the input space into simple regions, i.e. half-spaces separated
by a hyperplane. This works well for certain kinds of data but if applied to image
recognition, it results in insufficient invariance to position, orientation or illumination.
During the learning, the network (examples of the structure are described later), is
shown an image patch and it produces an output probability for it being a tumor. The
training dataset has images xi E RD, each associated with a label yi. Here i = 1... N
and yi 1 ... K. That is, we have N examples (each with a dimensionality D) and
K distinct categories. The score function f : RD -+ RK maps the raw image pixels
to class scores. An integral part of the multi-layered score function is regular non-
linearities, which distinguish it from a linear classifier.
This score is unlikely to be correct before training. We compute a loss function that
measures the error / distance between the output score and the desired score. We
use the cross-entropy loss with weight decay, with each training example additively
contributing Li = fy, + log Zj efi, where f refers to the vector of class scores. Mini-
mizing this loss is equivalent to minimizing the Kullback-Leibler divergence between
the estimated class probability distribution and the underlying ground truth.
The network then adjusts its parameters (or weights) to reduce this error. The number
of these weights are in the order of millions, and typically require millions of training
examples to converge to a high enough accuracy. The adjustment of the weights is
performed by computing the gradient of the error with respect to each weight, and
then the weight is adjusted in the opposite direction, scaled by the learning rate 1.
If performed over multiple layers, this results in the widely used backpropagation
algorithm [30].
However, since computing the objective function over all the training examples could
be very slow, Stochastic Gradient Descent (SGD) is used as an approximation. It
divides the training data into a mini-batch of examples over which the gradient is
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computed. Increasing the mini-batch size trades off frequency of update for gradient
accuracy and smoothness [7], but in practice having hundreds of examples in a batch
is sufficient for a reasonable gradient estimate. We initialize weights to small random
numbers, accounting for the parameter count [28] and force activations throughout a
network to take on a unit gaussian distribution at the beginning of the training (Batch
Normalization [31]), along with L2 weight decay and dropout [58]). We further use
the Adam optimization technique [36], modeled as
m = 01 * m + (1 - i1) * dx
v = 02 * v + (1 - 02) * dx 2
where x is the gradient, m is the smoothened gradient, 1 is the learning rate, and
#1, 02 and c are hyperparameters. The trained network is finally run on a hitherto
unobserved test set (or in this case, a 15% validation set).
Convolutional architectures make the explicit assumption that the inputs are images,
which allows us to encode certain properties into the architecture. These then make
the forward function more efficient to implement and vastly reduce the amount of
parameters in the network. The ones detailed in Figure 3-6 are composed of the
following layers
* Input - holds the raw pixel values of the image, in this case an image of width
256, height 256, and with three color channels R,G,B.
" Convolution - computes the output of neurons that are connected to local re-
gions in the input, each computing a dot product between their weights and a
small region they are connected to in the input volume.
" ReLU - applies an elementwise non-linear activation function, such as max(O, x)
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" MaxPool - performs a downsampling operation along the spatial dimensions
(width, height)
" FC (fully-connected) - computes the final class scores.
We evaluate three deep learning network architectures for performing classification
between the normal and the tumorous patches - VGG [55], Inception [59] and Residual
Networks [29]. The newly-introduced ResNets perform better than the previous state-
of-the-art, as shown in Table 3.1
Network Architecture Accuracy
VGG-19 [55] 97.7%
Inception [59] 98.2%
ResNet-34 [29] 98.8%
Table 3.1: Performance of deep learning architectures
To bootstrap and learn from false positives, we extract additional negative samples
from the non-tumor regions (200 per WSI) and retrain the model with the enhanced
dataset.
Finally, we embed all the prediction (at stride 256) results into a likelihood (heatmap)
image. Each pixel contains a value between 0 and 1, indicating the probability that
the pixel contains tumor. Figure 3-8 and 3-9 present results of the patch classifica-
tion on one of the whole-slide samples (with the overlaid annotated tumor) and the
corresponding output likelihood map.
All experiments were performed with Torch [12] running on a server with 2x 8-core
Intel Xeon E5-2620 A2.1 GHz, 128 GB DDR4 RAM, 2 TB SSD and 8x GTX 1080
8 GB. 8 replicas were run the GPUs with asynchronous gradient updates and batch
size of 64 per replica. We used Adam [36] with c of 10-8, #1 of 0.9 and /2 of 0.999.
The initial learning rate was 0.07, with a decay of 0.5 every 1 million examples.
34
alit: 224
outut
sie: 112
Output
size: 51
Outu
sine: Is
output
sine: 14
le: 7
WoE: I
output
size: 112
34-layer residual
ImWe
n64 /2
VGG-19
Imape
PWa, /2
po, n
Id co" 256
I Sd WNv 216
3p al, /2
3d mm, m1
pol, /2
Md UP, 512
Sd-ills li
pool,/2
t 
"-
fts I
pWIt/2
t
*2o | 35
(a) VGG-19 (b) ResNet-34
1 1 /,'1
Output pool /2
size:56 I conv,64 i
ax cony, 64
3d m,64
an, 64
I3 con, 64
355 on, 64
output eize21 aim 126/ -
sins: 28
ad mm, 128
d am, i28
Id aim, 123
dm, P121
'uso121
Output
ouw,ize: 14ca,26
ad m'ISO
Ad -, 256* no
3d mmw, -
3d mmco 266
3d - 266as Mum ,i
Unv62M
MIleedm, 32
output ... ......
[u: I sn/2
I A".M Ili -se jna
.d IeM, I
Output
oeep"s
. ft 2 |_
n e ra A I - .
3.3.4 Post-processing of likelihood maps
We take as input a heatmap for each whole-slide image and produce as output a single
probability of tumor for the entire WSI. We extract 28 geometrical and morphological
features (skimage's regionprops [60]) from each heatmap, including the percentage of
tumor region over the whole tissue region, the area ratio between tumor region and the
minimum surrounding convex region, the average prediction values, and the longest
axis of the tumor region. We compute these features over tumor probability heatmaps
across all training cases, and we build a 50-tree random forest classifier to discriminate
the WSIs with metastases from the negative WSIs.
On analyzing the relative importance of each feature, the following proved to be the
most discriminatory -
1. With threshold = 0.5, the longest axis in the largest tumor region
2. With threshold 0.5, ratio of pixels in the region to pixels in the total bounding
box (extent)
3. Eccentricity of the ellipse that has the same secondmoments as the region.
(eccentricity)
4. Ratio of tumor region with threshold = 0.9 to the tissue region
5. With threshold = 0.5, the area of largest tumor region
3.4 Results and Discussion
We compared our classification receiver-operator characteristics to those previously
considered-state-of-the-art. We test it against the performance obtained from support
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vector machines trained on Histogram of Oriented Gradients (HoG) [15] features and
Oriented FAST and Robust BRIEF (ORB) [51] features of the input image data.
The ROC curves in Figure 3-7 show how using a deep network boosted the AUC
significantly.
Figure 3-7: Performance Characteristics on the Lesion Classification Task
ROC
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0.8-
0.6
0.4
- ResNet + RandomForest (AUC=0.948)
- - ResNet + SVM (AUC=0.94054)
02 - ORB-SVM + RandomForest (AUC-0.918165)
- - ORB-SVM + SVM (AUC-0.91402)
- HoG-SVM + RandomForest (AUC=0.8725)
- - HoG-SVM + SVM (AUC=0.8804)
0.0 0.2 0.4 0.6 0.8 1.0
False Positive Rate
We also note that swapping out a random forest classifier in the post-processing step
works better than a support vector machine, although not by much. We note that this
metric is overall a challenging one because of the potential for false positives increases
dramatically when a high level of patch-level predictions are obtained per slide. In
contrast, human pathologist rarely demonstrate false positives in their analysis [35].
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(a) Whole-slide image with annotated tumors in green
(b) Tumor likelihood map generated by the patch classification stage. Since
each pixel corresponds to a 256x256 patch in the original slide, the resolution is
65,000x lower.
Figure 3-8: Patch classification result sample 1.
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(b) Tumor likelihood map generatM by the patch classification stage.
Figure 3-9: Patch classification result sample 2.
Chapter 4
Algorithms for Lesion Localization
The precise localization of lesions in a whole-slide image, especially of those that are
very small in size is an important prognostic step, since the geometrical characteristics
of the abnormality - like the size, eccentricity, location with respect to other cells etc.,
inform the diagnosis. It also is extremely tedious and laborious for the pathologist
and is thus prone to errors. To explore a variety of methods to approach this task,
we use the same dataset as described in the previous chapter.
4.1 Evaluation Metrics
The lesion localization performance is summarized using the Free Response Operating
Characteristic (FROC) curve. This is similar to ROC analysis, except that the false
positive rate on the x-axis is replaced by the average number of false positives per
image. A true positive is considered if the location of the detected region is within
the annotated ground truth lesion. If there are multiple findings for a single ground
truth region, they are counted as a single true positive finding and none of them are
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counted as false positive. All detections that are not within a specific distance from
the ground truth annotations are counted as false positives. The final score is defined
as the average sensitivity at 6 predefined false positive rates: 1/4, 1/2, 1, 2, 4, and 8
FPs per whole slide image.
For each tumor region detected in the whole-slide image (WSI), the algorithm provides
the X and Y coordinates of the detected region together with a confidence score
representing the probability of the detected region to be tumorous.
4.2 Two-stage thresholding model
We aimed to identify all cancer lesions within each whole-slide image with as few false
positives as possible. We perform the pre-processing and patch classification steps
described in Chapter 3, but proceed differently for the post-processing steps.
" We first train a deep model MA using our initial training dataset described in
Chapter 3.
" We then train a second deep model MB with a training set that is enhanced
with a higher representation of negative regions adjacent to tumors. This model
MB produces fewer false positives than MA but has reduced sensitivity.
" We threshold the heatmap produced from MA at TA, which creates a binary
mask.
" We then identify connected components within the tumor binary mask, and we
use the central point as the tumor location for each connected component.
" To estimate the probability of tumor at each of these (x, y) locations, we take
the average of the tumor probability predictions generated by MA and MB
across each connected component.
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(a) Whole-slide image with annotated tumors in green
(b) Tumor likelihood map thresholded at TA. Since
each pixel corresponds to a 256x256 patch in the origi-
nal slide, the resolution is 65,000x lower.
(c) Centres of connected components in the thresholded
map 42
Figure 4-1: Two-stage thresholding result sample.
4.3 Localization as Regression
To explore if we can directly train the convolution network to predict boundaries
of the tumor, we pose it as a regression problem for the location and size of their
bounding boxes, which are then accumulated rather than suppressed in order to
increase detection confidence. We apply this ConvNet at multiple locations in a
sliding window fashion over multiple scales (4 here), which are then merged. The
modified scheme for the network is shown in Figure 4-2. This method also avoids
using background samples resulting in much faster training and side-stepping the
bootstrapping process.
Figure 4-2: Architecture of the Bounding Box Regressor Network. The final fully-
connected layers in the original network are modified to introduce an additional head
trained with Euclidean loss.
Claw Score
UC
C f'stiou Cross-Entropy 
Loss
Feature Map
Conv/Pool
layersegs.o 8  p Bounding Box
x, y, w, h
Euclidean Loss
To generate object bounding box predictions, we simultaneously run the classifier
and regressor networks across all locations and scales. Since these share the same
feature extraction layers, only the final regression layers need to be recomputed after
computing the classification network. The output of the final softmax layer for a
tumor at each location provides a score of confidence that a tumor is present (though
not necessarily fully contained) in the corresponding field of view. Thus we can
assign a confidence to each bounding box. Training the regressors in a multi-scale
manner is important for the across-scale prediction combination. Training on a single
scale will perform well on that scale and still perform reasonably on other scales.
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However training multi-scale will make predictions match correctly across scales and
exponentially increase the confidence of the merged predictions.
We combine the individual predictions via a greedy merge strategy applied to the
regressor bounding boxes first introduced in [54].
1. Let C, be the set of classes in the top k for each scale s, found by taking the
maximum detection class outputs across spatial locations for that scale.
2. Let B, be the set of bounding boxes predicted by the regressor network for each
class in C,, across all spatial locations at scale s.
3. Let B = UsBs
4. Repeat until convergence:
* (b*, b*) = argminbj$b2 BMatchScore(b1, b2 )
* Stop, if MatchScore(b*, b*) > t.
* Else, let B = B\{b*, b;} U BoxMerge(b*, b*)
where MatchScore computes the sum of the distance between centers of the two
bounding boxes and the intersection area of the boxes and BoxMerge compute the
average of the bounding boxes coordinates. The final prediction is given by tak-
ing the merged bounding boxes with maximum class scores, which is computed by
cumulatively adding the detection class outputs associated with the input windows
from which each bounding box was predicted. An example illustrating the pipeline
is shown in Figure 4-3
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(a) Black rectangles mark the area under inspection
at this scale, while red rectangles mark the predicted
bounding box for that rectangle.
(b) High-confidence bounding boxes at multiple scale
cluster around the tumors when visualized
(c) Greedy merging of theAoxes by confidence results
in localization boxes for a particular scale.
Figure 4-3: The three stages of the localization-as-regression algorithm.
4.4 Region Proposal Network
To further examine joint learning methods for the localization task, we evaluate a
region proposal network (first introduced in [50]) to hypothesize object locations. A
RPN is a fully convolutional network that simultaneously predicts object bounds and
objectness scores at each position. Using the so-called "attention mechanism", the
RPN component tells the unified network where to look.
The implementation is divided into two modules (Figure 4-4). The first module is
a deep fully convolutional network that proposes regions and the second module is
the detector described earlier in Section 4.3, which uses the proposed regions. To
generate region proposals, we slide a small network over the convolutional feature
map output by the last shared convolutional layer. This small network takes as input
a 3 x 3 spatial window of the input convolutional feature map. Each sliding window
is mapped to a lower-dimensional feature, which is fed into two sibling fully connected
layers - a box-regression layer and a box-classification layer.
Class Score
hC5C3 Cross-Entropy Loss
Region
f.W Feature Map Proposal
Conv/Pool Network
layers Ressl Bounding Box
x, y, w, h
Euclidean Lose
(a) Modified bounding box regressor scheme with introduction of RPN.
1xI Cassif
Conv Object vs Not ObjectFeature Map W .- Pool Regions FC Layers
Convolution of interest
N.- Regress
cov Fine-tunod box loostjon
(b).
Figure 4-4: Schematic of the Fully Convolution structure of the RPN.
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This approach is translation-invariant, and can easily be extended to the multi-scale
setting with a pyramid of anchors [50]. However, we didn't observe significant boost
in the performance by incorporating more than one scale - most of the discriminatory
information for the pathology dataset appears to be at the highest magnification
detail.
4.5 Results and Discussion
We compare the performance (Figure 4-5) of the three methods described above, along
with a baseline of a very simple scheme of non-maxima supression which performs
the following steps until convergence -
1. Take the maximum in the likelihood map as the probability of tumor in the
entire image.
2. Set all values with a radius r of the maximum to 0.
The FROC metric is challenging because reporting multiple points per false positive
region can significantly erode the score. We focused on the FROC as opposed to the
AUC because there are approximately twice as many tumors as slides, which improves
the reliability of the evaluation metric.
We also experimented with models pre-trained on ImageNet [52] which improved
convergence speed in most cases, but failed to improve FROC, possibly due to the
large difference in the kind of information present in the natural scenes of ImageNet
vs the domain-specific pathology images, limiting the transferability.
Ensembling methods (averaging predictions from different augmentations, and aver-
aging predictions of multiple independently-trained models) failed to provide a sig-
nificant increase in the FROC score.
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Figure 4-5: Performance Characteristics on the Lesion Localization Task
Free response ROC
- RPN (0.7671)
- BoundingBox Regressor (0.7102)
- Two-Stage Thresholding (0.6981)
- Iterative Maxima (0.6797)
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Chapter 5
Algorithms for Patient Stage
Determination
Moving from the detection and localization tasks described previously to patient-level
analysis requires combining the detection and classification of metastases in multiple
lymph node slides into one outcome: a pN-stage. This task has high clinical relevance
and would normally require extensive microscopic assessment by pathologists of tens
of slides per patient. An automated solution for assessing the pN-stage in breast
cancer patients, would hold great promise to reduce the workload of pathologists,
while at the same time, reduce the subjectivity in diagnosis.
5.1 Dataset
In addition to the whole-slide images of hematoxylin-and-eosin stained lymph node
sections with lesion-level annotations, the dataset for patient-level analysis consisted
of 5 lymph node slides each for 100 patients in the training set, and 5 lymph node
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slides each for 100 patients in the test set, for a total of 1000 slides. Each slide had a
corresponding severity stage (negative, micro-metastasis, macro-metastasis, isolated
tumor cells (ITC)), but the ITC were not annotated exhaustively. Each patient had a
corresponding pN stage label. This data was collected from 5 different laboratories by
the providers and all ground-truth annotations were carefully prepared by expert-level
pathologists [22].
In actual clinical practice, tens of lymph nodes are surgically removed and processed
in the pathology laboratory. However, the size of the dataset would grow beyond rea-
sonable size if all the slides were shared, hence the providers forged artificial patients,
with 5 slides provided for each patient and each slide corresponding to exactly one
node.
5.2 Evaluation Metrics
Internationally, the TNM system is widely accepted [57] as a means to classify the
extent of cancer spread in patients with a solid tumour. It is one of the most important
tools for clinicians to help them select the suitable treatment option and to obtain
an indication of prognosis [9]. This prognosis usually worsens as the cancer spreads
[53]. In breast cancer, TNM staging takes into account the size of the tumour (T),
whether the cancer has spread to the regional lymph nodes (N), and whether the
tumour has metastasised to other parts of the body (M). The dataset we had access
to [22] focused on the pathologic N-stage (pN-stage) of the patients, which could be
one of five classes.
Thus, the evaluation metric used was a five-class quadratic weighted Cohen's kappa
coefficient, which measures inter-rater agreement with the pathologist provided ground
truth. [11]
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i= =k 1 - ~
where k is the number of classes (pN-stages) and wij, xij, and mij are elements in the
weight, observed, and expected matrices, respectively. The weights in the quadratic
set are defined as:
W i = I -
2
(k - 1)2
The score is zero if the procedure does no better than random chance.
5.3 Rule-based approach
To compose a pN-stage, pathologists counts the number of positive lymph nodes
(i.e. nodes with a metastasis). There are four categories a lymph node slide can be
classified into:
Slide category Rule
Macro-metastases Metastases greater than 2.0 mm.
Micro-metastases Metastases greater than 0.2 mm or more than 200 cells,
but smaller than 2.0 mm.
Isolated Tumor Cells (ITC) Single tumor cells or a cluster of tumor cells smaller than
0.2 mm or less than 200 cells.
Negative None of the above.
Table 5.1: Metastasis classification rules
ITC is strictly not a metastasis and therefore lymph nodes containing only ITC are
not counted as positive lymph nodes. However, pathologists are required to report on
ITC when no macro-metastases or micro-metastases were found in a patient's lymph
nodes.
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Figure 5-1: Examples of lymph node sections with different metastasis classifications
(micro-metastasis top-left, macro-metastasis right, isolated tumor cells bottom-left).
The extremely small size of micro-metastases and ITC on this zoom level illustrate
the tediousness a pathologist faces while examining each small subregion at a higher
magnification.
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Pathologic lymph node classification (pN-stage) is then defined as in 5.2.
Patient Rule
category
pNO No micro-metastases or macro-metastases or ITCs found.
pNO(i+) Only ITCs found.
pNlmi Micro-metastases found, but no macro-metastases found.
pN1 Metastases found in 1-3 lymph nodes, and at least one is a
macro-metastasis.
pN2 Metastases found in 4-9 lymph nodes, and at least one is a
macro-metastasis.
Table 5.2: pN-stage classification system rules
This methodology is a simplified version of the official recommendations of the Union
for International Cancer Control and the American Joint Committee on Cancer [46],
due to lack of fine-grained data on lymph node's location of origin and molecular
techniques like RT-PCR.
We modify our post-processing step defined in Section 3.3.4 to classify into 4 categories
- macrometasis, micrometastasis, ITC and negative, instead of just the two as earlier.
We retrain the random forest classifer and then apply the rules as described above to
get a final pN stage for the patient.
5.4 Joint Learning of slide label and pN stage
The pN stages provided in the dataset are consistent with the individual whole-
slide labels, and the rules for determining the stage as described earlier. The rule-
based approach's limitations are only (at least in this context) caused by imperfect
classification into the four classes.
To explore the possibility of a model which bypasses the explicit step of learning
the individual whole-slide label, and learns the pN stage directly from the individ-
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Figure 5-2: Architecture for directly learning the pN stage of the patient from whole-
slide images, rather than first explicitly learning the slide class label.
Patient X
Slide 11 CNN,
Slide 2 CNN
Slide 3 CNN, -pN Stage
Slide 4A
Feature Maps
ual slides, we restructure our network architecture (Figure 5-2) We run the patch-
classification and recombination into heatmaps. as before, but now train a new deep
network (ResNet-34) with each patient's 5 slides as a stacked input image of 5 chan-
nels, to classify between the five pN stages. We boost the weight decay to avoid
overfitting with the low number of examples.
5.5 Results and Discussion
We obtained the scores of Table 5.3 in the Cohen's Kappa evaluation metric. We
note that the joint-learning approach boosted the score significantly, indicating that
directly using the pN stage as the variable to be corrected reduced the build-up of
errors from explicitly making an intermediate classification.
In particular, we also noted that the isolated tumor cells (ITC) were not exhaustively
annotated in the ground truth set. If we replaced the labels of the slides marked as
ITC to negative or to micro-metastases, we observe a minor improvement in perfor-
mance.
The Kappa metric is challenging since even with quadratic weighing, the proximity
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Method K score r, score with r, score with
ITC as negative ITC as microm.
Joint-learning 0.8758 0.8921 0.8914
Rule-based approach 0.8386 0.8452 0.8435
Average Pathologist [17] 0.7 (Estimate) - -
Random Chance 0.0000 .0.0000 0.0000
Table 5.3: Performance on the patient stage determination task
between individual classes is unaccounted for. Moreover, the highly critical nature
of detecting all positives, at some cost of false positives, can only be captured by ad-
justing the weights accordingly. Nevertheless, the performance of the algorithms is a
good indicator of the inter-rater agreement, which surpasses the average pathologist's
score of 0.7 [17].
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Chapter 6
Analysis of Deployment Strategies
An automated histopathological analysis platform could help the lives of millions of
Indians who require screening and diagnostic services every year, by enabling a reduc-
tion in reliance on hard-to-acquire experts, increase in throughput, and improvement
in efficiency. It could be effectively deployed into the diagnostic pipeline of existing
organized pathology lab chains, recuperating initial costs effectively over time while
simultaneously getting better in terms of accuracy as access to more continuous data
is made available. We present here a quantified articulation of a business model
including activities, resources, customers, channels, costs, revenue streams and the
value added.
6.1 Quantified Value Articulation
The healthcare industry amounts to over $80 billion in India, with over $1 billion
directly coming from the domestic pathology market (growing at 20% compounded
annual growth rate), mostly in Tier I cities [19]. This growth is heavily driven by
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Figure 6-1: A business model canvas for deploying and commercializing the technologies and algorithms described in the
previous chapters
Comm P1e9m-6a-ah I uch * DevulupueIf
For gLMing research by Bud voo--ncapt
pAn sanoles and technoogy into plnorm
MenAn curc APMMAW-amcying
~ ApdemTo pathology WEbs
For enawing all testing hospamas, clnics and
and valldation foows government
legal-
....... .. .
Bimrn Dmus
To buld the platform and
scile the tech.
SerVQrM high-
Pei rnrmnce nwdhins
and ~vk
Coot stnm*Ame
C Hstm maaareh/ bglinee
sihutluiS Od & Labelds
Whte ftrma Qdstm srnm w-"M cutmrSugmeni.
SOreaning Thfmaghp* Oa~tony tprviug Priinct Patmlgy eLabe
Increasing speed of Through learning from Prbmary adopters
routine cbeckl by new data
providing fast preditionsesa
TechriAw SHOP at
uLow-cost screening
For platform and tools makes more
Increasing eo. of people dlsrCINVnalve diagnoses
with access to tech possible, could reduce
ou"PourSng
Seducad Rualance an xprts
Niftn Meedical UftftSCWn screening am... .............................
augmenting a'State-sponsored last mile
rWOMW qwnda"ow 90rvkce
airedm SMSCon"Oh"Mn Quality
i To pathology lwbs andUnlttdby dhoerse-- -clinicssubjective opinions
s InotPartmarGhIAW
Through MU. SuMkes
etc
Seftwae esn -nitc
Matwara W a Service
changing disease profile of the population and consequent interest in screening and
follow-up, including cancer markers in the recent past [37]. It is estimated to account
for 2.5% of the healthcare delivery market [33]; conversely, it is also estimated to
comprise 52% of the medical device market [37]. Like other healthcare services,
laboratory testing is unevenly distributed across India. Research suggests that only
one-third of the rural population has access to diagnostic centers and perhaps only
one-half of public-sector facilities offer treatment for chronic illnesses [18]. The costs of
delayed, inaccurate or inconsistent pathological screening and diagnostics invariably
seep into the larger figure.
There are several problems to be confronted in this sector -
1. Only about 1% of the laboratories are accredited (e.g. by the National Ac-
creditation Board of Laboratories) or certified (e.g. by the College of American
Pathologists). There is no quality regulation in this sector; center operators
do not require registration or certification of lab testing instruments or clinical
processes.
2. There is little use of IT, automated equipment, and quality or statistical analyses
run on this equipment outside of the organized sector.
3. As a result of the first two factors, there is reportedly a large variation in lab-
oratory performance across India, which has significant negative consequences
for patient diagnosis, treatment and follow-up.
A pathology expert in India earns around $30,000-$80,000 per year, far above average
of comparable fields of expertise. This directly stems from low supply and high
demand, with each pathology test and analysis costing anywhere between $100-$300,
where over 75% of the cost is due to the analyses rather than the physical collection
and processing. If an automated system is used as a first line of defense, and assuming
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75% of the cases can be classified as benign or malignant by the system, it can drive
costs down to $50-$150 if amortized over the cost of setting up the system. This
can translate into enough capability to hire over 2 to 3 times more experts, helping
pathology labs scale up their operations and expand into newer markets.
Currently, to analyze tissue samples of patients for indications of conditions like
cancer, anemia, tuberculosis etc., they are usually extracted at a local hospital or
clinic, and then either physically sent to a pathological expert without imaging ( 1
week), or digitized with a microscope at a collection center and sent to a pathological
expert online. (usually 2-3 days). An automated analysis system, if combined with
the collection / digitization facilities can reduce the turnaround time to a few minutes
for most cases, thereby heavily increasing throughput and helping direct care to those
who need it most urgently.
Figure 6-2: The collection center model for histopathological analyses in India.
Reference Lab
Satellite Lab Satellite Lab
Collection Collection Collection Collection
Center Center Center Center
The quality of analysis and recommendations varies wildly with demography, exper-
tise and cost / time currently, but having an automated system can help inform con-
sistent metrics for counsel, introducing equity in analyses regardless of the patient's
conditions or financial status.
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6.1.1 Channels
Direct sales to pathology labs and clinics could be the biggest channel for deployment
of the service. Each lab spends over $15-$40 per hour on an expert and a licensing
model which make the software available as a service for remote use can be priced at
a fraction, say $5-$10 per hour, and still be profitable because of the mostly one-time
(initial) nature of the investment, which can be amortized over a long period and the
costs recuperated.
An alternative to direct sales could be through partnerships, especially with the
central and state governments, which are heavily invested in providing improvements
to health care, increase life expectancy and provide connectivity to hard-to-reach and
thus untapped geographies. Subsidies to the order of 30-40% aren't unheard of and
can help drive adoption by bigger commercial players.
6.1.2 Revenue Streams
The primary revenue streams would be based on providing the platform software,
either on a licensing model or as a remote service, with the pricing based on number
of analyses performed or amount of data analyzed. A price-point of $10 per patient
analysis could result in over $10 million of revenue per year, while still recovering the
initial cost of investment, and yet being cost-effective for the pathology labs. Also, as
the accuracy of the platform improves with more available data to analyze, its value
would appreciate, rather than depreciate, over time.
A de-identified demographic analytics layer, on top of the actual assessment platform
could also be immensely valuable as a tool for policy makers, hospital administrators,
and consultants. This could potentially form an alternative secondary revenue stream.
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6.1.3 Cost Structure
The computation resources required to train statistical models and host the cloud-
platform would be a key investment initially, for research and development. A power-
ful machine for the former could cost $10,000 - $15,000 and the latter can cost $1,000
- $2,000. The number of servers would need to scale to handle the load of servicing
once the platform is deployed and could handle 3-5 active analyses simultaneously,
resulting in $10,000 - $15,000 on machines per pathology lab, if 25 technicians utilize
it at once.
The research and engineering efforts would also require a significant investment in
terms of expertise in machine learning systems and scalable cloud-based software
development. A team of 3-5 competent engineers, could require an investment of
$300,000 - $500,000 per year in the development phases. The sales and marketing end
of things would also require effective personnel for business development and support,
and depending on the number of clients / customers, could cost over $500,000 per
year.
Access to datasets and corresponding annotations (to build statistical models from)
is probably the most uncertain investment in terms of pricing at this point. There
are a few public datasets available for certain histopathological tasks but a commer-
cial solution would inevitably need access to a sizable amount of custom annotated
data. There are a few companies (e.g. Advanced Tissue Services, Asuragen etc.)
which provide samples, digitized or otherwise, at prices ranging from $0.20-$2 per
slide. An analysis of the tradeoff between amount of data required vis a vis expected
performance would require more experiments at this point.
The bulk of the initial effort would be in research and development for the platform,
including but not limited to data collection, machine learning engineering, web server
development and cloud-based scaling. Investment for the same could amount to $1
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million - $3 million as computed earlier, but would be recovered over time from sales.
The subsequent investment would be in marketing the service to pathology labs and
clinics, as either a SaaS or as a software licensing model. The costs involved with
business development are highly variable but are expected to be 30-60% of the
engineering costs, based on historical data of similar software-oriented solutions.
6.2 Customer Segments
The key customer segments include organized and unorganized diagnostic labs, hospi-
tals and clinics, and state-sponsored initiatives like mobile medical units and subsidies.
Organized Unorganized Hospitals Mobile
Labs Labs Medical Units
End User Pathologists Pathologists & Clinicians & State
& Technicians Nurses Government
Technicians Employees
Buyer Lab Chain Lab Owner Hospitals State
Government
Applications Screening & Screening & Preliminary Last-mile
Diagnostics Diagnostics Screening & health care
Diagnostics connectivity
Benefits Penetration Competitive Not reliant on Faster
into Tier II / advantage over path labs turnaround
III markets organized labs time
Market Size $1b total 80% of lab Hospital 1500+ units,
market, rapid market services $2b 38m+ patients /
expansion year
Table 6.1: Breakdown of key customer segments
The organized sector has arisen in recent years to build a national network and
develop a more capital-intensive segment ducting high-margin testing. To develop
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this network, firms have begun to enter Tier II and Tier III cities, typically via
acquisitions and brownfield projects. It is by far the most consolidated segment,
with clear key players, and a predictable growth trajectory. They have employed
variants of the hub-and-spoke model in which they operate central reference labs in
large metropolitan areas and partner with satellite and feeder labs as well as hospital
collection centers.
Automated solutions and systems will only benefit them by reducing inefficiencies,
providing a consistent quality of service and keeping costs low, and thus they might
be more willing to help validate and test experimental technology. Each lab employs
1000-3000 experts, and the big chains (5-8 in number) have tens to hundreds of refer-
ence labs spread around the country, but mostly concentrated in major cities. Some
of these labs include -
Pathology Lab Number of Labs Collection Centers
Dr Lal Path Labs 35 600
Metropolis 50 350
SRL Diagnostics 35 800
Piramal Diagnostics 104 300
Table 6.2: Characteristics of notable diagnostic lab chains
The majority of the market share however (estimated to be as high as 85-90%) is
captured by the unorganized sector [56]. The small operations have proliferated due
to lack of regulation and requirements for accreditation in this sector; they also have
comparably lower costs and referral ties to physicians, who may receive kickbacks for
patient testing, which may explain their prevalence [37]. Incorporating automated
analyses systems can help them compete better with bigger players who might have
more access to expert talent.
The laboratory plays a critical role in the delivery of Indian healthcare; one estimate
suggests that as much as 70% of all medical decisions are based on laboratory re-
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sults. Hospitals, particularly those with fewer than 250 beds (which comprise the
vast majority of Indias facilities), often outsource much of their diagnostic testing to
large freestanding laboratories. This outsourcing approach, sometimes referred to as
hospital laboratory management (HLM), seeks to take advantage of aggregated test
volumes and scale economies. Only about 10% of Indian hospitals (primarily private
facilities) have their own laboratories. However, if an automated preliminary screen-
ing system is deployed, they would be able to reduce the reliance on outsourcing for
all cases, and only consult pathology labs for low-confidence or high-risk cases.
There has been a recent aggressive push towards deploying mobile medical vans /
units (MMUs) at different levels by state governments. About 1500 of them are
currently active across the country, primarily in Orissa, Jharkhand, Maharashtra and
a few other states, with rapid expansion plans [62]. Each of them services an average
of 25,000 patients per year providing last mile access. Theyre outfitted with X-Ray
machines, ultrasound, blood collection and tissue collection facilities. The service
costs an amortized Rs. 150 per patient. They suffer from sample degradation during
transportation and delays in obtaining results. They would benefit heavily if faster
analyses of collected samples was available.
Each segment has their pros and cons in terms of initial deployment support and
offerings, but the organized diagnostic lab sector could be a good starting point since
they have a number of benefits to reap from such a system and market forces help in
incentivizing it, thus positioning the project in a favorable position to move forward.
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Chapter 7
Conclusions
7.1 Summary
The histological assessment of human tissues has emerged as a key challenge for
detection and treatment of multiple clinical conditions, including cancer. Experts
analyze slide images in order to characterize samples by performing tasks like whole-
slide classification, tumor localization etc. whose results inform the diagnosis. But
a mismatch between demand and supply of experts, especially in the Indian setting
and the rural context, has led to suboptimal quality and turnaround times.
The proposed automated platform for large-scale histopathological screening pre-
sented in this thesis can help automate preliminary analysis tasks, massively reducing
reliance on expensive experts, increasing throughput and accuracy, providing consis-
tent results over widely varying cases, while still allowing humans to verify and have
the final word on any grading. It can help reduce inefficiencies in scaling and expand-
ing diagnostic services, while still being compatible with existing diagnostic pipelines
and procedures. It could be effectively deployed into the diagnostic pipeline of ex-
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isting organized pathology lab chains, recuperating initial costs effectively over time
while simultaneously getting better in terms of accuracy as access to more continuous
data is made available.
In Chapter 3, we described algorithms to classify whole-slide images of sentinel lymph
node tissues extracted from patients into normal or tumorous. We described a clas-
sification pipeline, with pre-processing of background removal, stain normalization
and data augmentation, followed by patch-wise classification with a deep-neural net-
work to output a likelihood, and finally post-processing of the likelihood map with a
random forest trained on the geometric properties of the tumor to give a class label.
In Chapter 4, we detailed algorithms to localize the lesion in the whole-slide image,
using three approaches - a two-stage thresholding model which oversamples tumor-
adjacent regions to achieve high discriminability, a bounding box regressor model
which learns to predict the bounding box at multiple scales which are then merged
greedily weighted by confidence, and a region proposal network addition to the re-
gressor which identifies regions of high interest.
In Chapter 5, we discussed algorithms for determining the clinical stage of the patient.
We contrasted the traditional rule-based approach with a novel joint-learning method
which bypasses the intermediate explicit lableling of individual slides in favor of an
end-to-end pN stage classification.
Finally, in Chapter 6, we examined and articulated deployment strategies for a health-
care software solution encompassing these algorithms in the Indian setting, including
the market state, distribution channels, revenue streams, associated cost structure
and key customer segments.
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7.2 Future Work
The algorithms described in this thesis perform well for the tasks for which they
are trained, but lack they currently lack the breadth of knowledge and experience
of human pathologists for example, being able to detect other abnormalities that
the model has not been explicitly trained to classify (e.g. inflammatory process,
autoimmune disease, or other types of cancer). Gathering more data to that end and
tuning the models to recognize more pathological cases will improve performance on
such 'hitherto unspecified' tasks and make for a more robust real-world solution.
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